BeOne Medicines (BEIGF) EBIT Margin (2015 - 2026)

BeOne Medicines (BEIGF) has reported EBIT Margin for 12 consecutive years, with 19.06% the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBIT Margin rose 1238.0% year-over-year to 19.06% in Q2 2026; TTM through Jun 2026 was 15.06%, a 1727.0% increase from a year earlier, with the FY2025 full-year figure at 8.37%, up 2328.0% from the prior year.
• EBIT Margin was 19.06% for Q2 2026 at BeOne Medicines, up from 16.51% in the prior quarter.
• Over five years, EBIT Margin peaked at 19.06% in Q2 2026 and troughed at 144.57% in Q1 2022.
• A 5-year average of 40.1% and a median of 14.58% in 2023 frame the typical range for EBIT Margin.
• The widest YoY moves for EBIT Margin: up 18794 bps in 2022, down 15615 bps in 2022.
• Over 5 years, EBIT Margin stood at 123.29% in 2022, then soared by 51 bps to 60.5% in 2023, then soared by 88 bps to 7.04% in 2024, then soared by 275 bps to 12.35% in 2025, then soared by 54 bps to 19.06% in 2026.
• The last three EBIT Margin figures came in at 19.06% (Q2 2026), 16.51% (Q1 2026), and 12.35% (Q4 2025), per Business Quant data.